TRB Stock Overview
Acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Trinity Biotech plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.12 |
| 52 Week High | US$4.75 |
| 52 Week Low | US$1.69 |
| Beta | 1.24 |
| 1 Month Change | 0% |
| 3 Month Change | -7.42% |
| 1 Year Change | -50.12% |
| 3 Year Change | -83.82% |
| 5 Year Change | -79.22% |
| Change since IPO | -96.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| TRB | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.9% | 1.4% |
| 1Y | -50.1% | -7.1% | 9.1% |
Return vs Industry: TRB underperformed the German Medical Equipment industry which returned -3.4% over the past year.
Return vs Market: TRB underperformed the German Market which returned 4.3% over the past year.
Price Volatility
| TRB volatility | |
|---|---|
| TRB Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: TRB has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine TRB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 380 | John Gillard | www.trinitybiotech.com |
Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren’s syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders.
Trinity Biotech plc Fundamentals Summary
| TRB fundamental statistics | |
|---|---|
| Market cap | €13.77m |
| Earnings (TTM) | -€33.95m |
| Revenue (TTM) | €52.33m |
0.3x
P/S Ratio-0.4x
P/E RatioIs TRB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRB income statement (TTM) | |
|---|---|
| Revenue | US$56.83m |
| Cost of Revenue | US$37.38m |
| Gross Profit | US$19.45m |
| Other Expenses | US$56.32m |
| Earnings | -US$36.87m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.89 |
| Gross Margin | 34.22% |
| Net Profit Margin | -64.87% |
| Debt/Equity Ratio | -229.1% |
How did TRB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/20 02:22 |
| End of Day Share Price | 2024/02/22 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Trinity Biotech plc is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laura McGuigan | B. Riley Securities, Inc. |
| Lawrence Solow | CJS Securities, Inc. |
| William Bonello | Craig-Hallum Capital Group LLC |